Rise in weight-loss drugs prescribed to combat childhood obesity

Sep 03, 2009

Thousands of children and adolescents are using anti-obesity drugs that in the UK are only licensed for use by adults. The number of young people receiving prescriptions for these drugs has increased 15-fold since 1999, but most stop using them before they could expect to see any benefit, according to a new study.

The study, published in the British Journal of Clinical Pharmacology, focuses on prescriptions in the UK, where the drugs are not licensed for use under the age of 18. Extrapolated across the whole population, the results indicate that around 1,300 are now being prescribed off-licence anti-obesity drugs each year.

More than three quarters of those included in the study received prescriptions for orlistat, also known as Xenical or Alli. Orlistat has been approved for children as young as 12 in the US, but only for in the UK. Most patients given orlistat stopped using it very quickly, on average after just three months, and therefore would have been unlikely to see any benefit.

"It's possible that the drugs are being given inappropriately, or that they have excessive side effects that make young people discontinue their use. On the other hand they could be expecting the drugs to deliver a miracle "quick fix" and stop using them when sudden, rapid does not occur," said Russell Viner, one of the authors of the study based at the General & Adolescent Paediatrics Unit at University College London.

As anti-obesity medications are expensive, not sticking to drug programmes wastes valuable resources. Study author Ian Wong says that children who are prescribed orlistat may need more support and should be made fully aware of the potential side effects, which include loose, oily stools if fat intake is not reduced.

"You have to tell them that, yes, it is healthier not to absorb the fat, but if they continue to eat as much as they used to then it will be really unpleasant. The key thing is that the drug itself is not the answer. Kids should only be using it as part of a comprehensive weight-loss programme," said Wong.

The researchers used data from the General Practice Research Database, which covers around 5% of the UK population. 452 children and adolescents were prescribed anti-obesity drugs between 1999 and 2006. Over eight years, the number of young people receiving prescriptions rose 15-fold from 0.006 per 1,000 to 0.091 per 1,000.

According to the researchers, it is highly unlikely that the drugs are doing any damage, as well-conducted short-term clinical trials did not report life-threatening side-effects in young people. But they say further research into the safety and efficacy of anti-obesity drugs in children and in clinical practice is warranted, particularly considering the dramatic increase in prescriptions and likely further increases due to childhood obesity globally.

Source: Wiley (news : web)

Explore further: FDA OKs Cubist antibiotic for serious infections

add to favorites email to friend print save as pdf

Related Stories

GPs 'could do more' to help obese avoid surgery

Dec 17, 2008

Surgery to treat obesity could be avoided if GPs and healthcare trusts put more time and money into early stage weight management programmes, a senior clinical researcher will say today.

Fatty liver disease medication may have no effect

Jan 13, 2009

A new randomized, prospective trial has shown that orlistat, a commonly prescribed inhibitor of fat absorption, does not help patients with fatty liver disease (FLD) lose weight, nor does it improve their liver enzymes or ...

FDA panel backs 3 psychiatric drugs for kids

Jun 11, 2009

(AP) -- Advisers to the Food and Drug Administration said Wednesday that three blockbuster psychiatric drugs appear safe and effective for children and adolescents, despite side effects that can increase the risk of diabetes.

Recommended for you

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.